SPECIAL ARTICLE

©American College of Medical Genetics

Genes and plays: bringing ELSI issues to life
Karen H. Rothenberg, JD, MPA1,2 and Lynn W. Bush, PhD, MA3
Ethical complexities surround the promise of genomic technology
and the power of genetic information as they alter conceptions of
identity and dynamics within personal and professional relationships.
Creative approaches such as dramatic vignettes offer a unique analytical stage for imagining the bioethical past and future. Dramatic
narratives can bring to life images of differing perspectives and values
when experiencing innovations in medicine. Although the scientific
landscape shifts, concerns expressed in theatre from 50 years ago parallel many contemporary ELSI (ethical, legal, and social implications)
issues, highlighting the ongoing struggle to appreciate the impact of
emerging genetic technologies on relationships. To illuminate these

enduring concerns, we explore how perceptions and relationships
have influenced—and been influenced by—genetics as portrayed
through dramatic vignettes. We build on the legacy of using case
vignettes as a clinical teaching modality, and believe similar value
exists within the research ethics domain. The selection of dialogue
discussed encompasses abbreviated excerpts from two existing and
one original vignette that we staged at the ELSI 2011 Congress and
various academic and health institutions.

INTRODUCTION

Medicine & Imagery in Theatre. Varying lengths and combinations of dialogue were briefly rehearsed, enacted, and
witnessed by groups that included bioethicists, geneticists,
genetic counselors, policy makers, and students at the ELSI
2011 Congress (held in Chapel Hill, North Carolina, 11–14
April 2011), National Human Genome Research Institute,
Columbia University, and University of Maryland Francis
King Carey School of Law.
Session notes with near-verbatim quotes from volunteer
actors and the audience at the ELSI Congress parallel many
responses elicited when our dramatic vignettes have been
performed elsewhere. We selected both past and current
dialogue representing a small sample of possibilities that
illuminate affective responses within personal and professional relationships to genomic technology with contrasting
contextual subtleties.
Although celebrated as a play about dysfunctional marital
relationships, Edward Albee’s 1962 Who’s Afraid of Virginia
Woolf  26 also directly addresses many societal concerns raised
by the threat of genetic manipulation and its implications for
future generations. Set on a college campus, George and Martha
are at their home getting acquainted with a young science professor and his wife:

Ethical complexities surround the promise of genomic technology and the power of genetic information,1–5 as they alter
conceptions of identity and dynamics within personal and professional relationships. Creative approaches such as dramatic
vignettes offer a unique analytical stage for imagining the bioethical past and future.
Theatrical narratives can illuminate both complementary and
disparate views,6 bringing to life images7–9 of often conflicting experiences and perspectives when encountering new genetic technology and information. Although the scientific landscape shifts,
concerns expressed in theatre from 50 years ago parallel many
contemporary ELSI (ethical, legal, and social implications) issues,
including the ongoing struggle to appreciate the impact of emerging genetic technologies on relationships. Therefore, to enhance
our current discourse on these enduring concerns as we translate
genomic innovations from “base pairs to bedside,”10,11 we have
found it useful to reflect on their constancy by exploring how perceptions and relationships have shaped—and been shaped by—genetics as portrayed through three dramatic vignettes spanning half
a century.
We build on the legacy of using case vignettes as a clinical teaching modality, to facilitate empathy (through film,12,13
plays,13–19 television,20,21 literature,22,23 narrative prose,24) or
bring to life legal controversies,25 and believe similar value
exists within the research ethics domain. The selection of dialogue (below) encompasses abbreviated excerpts from two
existing and one original vignette that we have staged at various academic and health institutions over a 2-year period as
part of our comprehensive bioethics project, Innovations in
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GEORGE:	 Martha says you’re in the Math Department . . .
NICK:	I’m a biologist. I’m in the Biology Department.
GEORGE:	you’re the one’s going to make all that trouble . . .
making everyone the same, rearranging the
chromozomes, or whatever it is. Isn’t that right?
NICK:
Not exactly: chromosomes.

University of Maryland Francis King Carey School of Law, Baltimore, Maryland, USA; 2National Human Genome Research Institute, Department of Bioethics, Clinical Center,
National Institutes of Health, Bethesda, Maryland, USA; 3Department of Clinical Genetics, Columbia University, New York, New York, USA. Correspondence: Karen H. Rothenberg
(krothenberg@law.umaryland.edu)
Authorship is equally shared for the article and original play.
1

Submitted 30 September 2011; accepted 18 October 2011; advance online publication 19 January 2012. doi:10.1038/gim.2011.47

274

Volume 14 | Number 2 | February 2012 | Genetics in medicine

Genes and plays: bringing ELSI issues to life | ROTHENBERG and BUSH

GEORGE:	. . . do you believe that people learn nothing
from history? Not that there is nothing to learn,
mind you, but that people learn nothing? I am
in the History Department . . . Biology, hunh? I
read somewhere that science fiction is really not
fiction at all . . . that you people are rearranging
my genes . . . [later in dialogue]
MARTHA:	(To Nick) Georgie-boy here says you’re terrifying. Why are you terrifying? . . .
HONEY:
It’s because of your chromosomes, dear . . .
GEORGE:	. . . Martha, this young man is working on a
system whereby chromosomes can be altered . . .
the genetic makeup of a sperm cell changed,
reordered . . . to order, actually . . . for hair and
eye color, stature . . . I imagine . . . and mind . . .
All imbalances will be corrected, sifted out . . .
We will have a race of men . . . test-tube-bred . . .
incubator-born . . . superb and sublime . . . But
of course there will be a dank side to it, too.
NICK:
(Grimly) Now look! . . .
Much as contemporary CP Snow espoused in his The Two
Cultures and the Scientific Revolution27 regarding the differing
values and perspectives of the Sciences and the Humanities,
Albee is exploring the disharmony surrounding the biologist
who creates and manipulates the future and the historian who
reflects on the past as prologue. Their perceptions and presumptions about balancing the risks and benefits of genetic
manipulation reflect the dichotomy of their worldviews. In a
recent staging of this vignette at a National Human Genome
Research Institute forum, a genomics researcher playing Nick
shared his frustration with George’s character, reflecting that
this is how some scientists may feel when questioned by the
bioethics community.
Albee’s carefully crafted dialogue brings to life the persistence
of concerns we still face today—the fear of genetic innovations
transforming human relationships and individual, familial,
and cultural identities. While contemporary ELSI issues echo
debates of an earlier time as society continues to search for biological explanations and solutions, these persistent challenges
emerge with increasing frequency as genomic advances generate more and more information.28 For example, assessing the
promises and perils of medical innovations are rendered more
complex when these assessments depend on definitions of what
is “normal.” Drama that expresses our hopes for a world free of
disease and our fears for life devoid of human individuality29
provides insight into who will and should determine whether
a given heritable trait is good or bad enough to be subject to
genetic manipulation.
Reflecting the recent acceleration of scientific technologies,
Dorothy Fortenberry’s 2010 The Good Egg30 examines how
preimplantation genetic diagnosis holds out the theoretical
possibility for preventing the heritable transmission of bipolar disease, and dramatizes potential ethical and psychological
ramifications on relationships. The tension in this play revolves
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around Meg, a single woman who wants to preselect “healthy”
eggs with assisted reproductive technology—supported and
encouraged by her gynecologist Adrianna (unseen though referenced throughout)—and Meg’s brother Matt, who resides
with her and is diagnosed as bipolar, just like their dad who
committed suicide:
MEG:	It’s a really routine procedure . . . To check for disease, abnormality, to make sure the baby’s healthy
and normal and—
MATT:	Not bipolar . . . You didn’t think I’d find out? You said
they were checking for diseases—
MEG:	And they are. For Huntington’s and Parkinson’s and
Alzheimer’s and MS and—
MATT: Me?
MEG:	It’s a new test. They just located the genes recently,
and—
MATT:	You’re taking advantage of the technology. It’s on
the Metropolitan Fertility website . . . Like “New!
Improved! Now with no bipolar!” . . .
MEG:	It is a totally routine, common thing to do, just to be
on the safe side. I like the safe side. That’s all it is.
MATT:	Um, no, it’s rifling through a selection of babies—fine,
fine of embryos—and then choosing your favorite,
which is totally weird and gross and disgusting.
MEG:	It didn’t disgust you when I told you they were screening for Down syndrome.
MATT: That’s different.
MEG: How? (He can’t say.) . . . [later in dialogue]
MATT:	. . . You are trying to delete me from our family. You
are genetically editing me from the code of who we
are. You’re eliminating me and you’re eliminating
Dad.
The dialogue highlights an inherent moral challenge—
the explicit predetermination of what type of child a person
would be willing to parent—which, in this scenario, ultimately threatens Meg’s relationship with her brother. The tension between the utilization of these cutting-edge technologies and the value-laden choices these innovations create raise
dilemmas for individuals, families, the medical community,
and society regarding limits on technologies that have the
potential to change the fate of others. Dramatic vignettes can
illuminate the implications for such choices to alter someone’s
future because of a perceived lack of normalcy, and the contentious disagreements that could arise if family members or
others in society can be “deleted.”
Different judgments about “what is normal” are shaped
by our experiences and cultural expectations, which directly
impact how we frame our identities and those of others. In turn,
these perceptions color our presumptions about the power of
science and technology to control our destiny. Despite Matt’s
strong feelings, Meg was adamant in her beliefs that the use
of these innovative technologies would provide the path to a
better place.
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In response to enacting this vignette, a National Human
Genome Research Institute science educator remarked that
even though she has never been pregnant, she felt an enormous sense of responsibility to do the “right thing”—although
she was uncertain what that might be. Several researchers and
social scientists witnessing the dialogue spoke of a moral
conundrum: “Why was a Down’s test OK for Matt when he
was so adamantly opposed to bipolar?” One noted that this
vignette raised awareness of “the need to be sensitive to different views that folks have about what they are willing to
parent” and another commented to be “cautious not to make
value judgments about others.” In a subsequent staging, bioethics students remarked that witnessing the deteriorating
relationship of the siblings brought to life the gravity of differing views on accessing emerging technologies. A science
professor pointed out that acting and watching the parts in
drama—experienced from a sufficient distance apart from
one’s self—allowed for a “safer” discussion of the emotional
and controversial issues underlying the judgments raised in
The Good Egg.
While The Good Egg offers an opportunity to observe implications of cutting-edge technology in clinical practice, It’s Not That
Simple! 31 (Supplementary Data online)—the first in our series of
original dramatic vignettes—turns to the emerging ethical challenges raised by next-generation sequencing. It illuminates the
real challenges of informed consent for genomic research and
sharing genetic information among family members, each with
different values, and illustrates the difficulties that may arise from
the multidimensional roles of the physician/researcher/geneticist
through our character Dr Hardy:
DR HARDY: In fact the reason I gathered you all here today
is that I have some good news. We now have
a better chance to understand what’s causing
your disorder—and you can be part of a new
study . . .
The dynamics of this play further revolve around the
Friedman family—Mom, 19-year-old Bobby and 16-year-old
Amy (both with an autosomal recessive disorder), and 9-yearold Sam—as they discover and ponder the many questions
raised for each of them in deciding the amount of information
they want to receive after being sent home by Dr Hardy to read
the informed consent form:
BOBBY:	But what if Amy wants to know everything and you
don’t, and it turns out both you guys have something like the BRCA gene you hear about so much?
And what about Sam?
SAM:	Don’t worry about me. I’m the healthy kid in the
family.
AMY:	Of course I’d want to know everything—we’d all
want to know.
MOM:	Don’t jump to any conclusions Amy . . . you can’t
speak for the whole family . . . I would not want any
276
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of us to know if something bad is going to happen
way into the future . . .
AMY:	The consent form also said something about our
relatives learning results.
MOM:	My relatives? . . . If the doctors find something, I’ll
just keep it a secret.
BOBBY: A secret? You’re terrible at keeping secrets, Mom.
AMY:	That nice genetic counselor can always tell Aunt
Rachel and Aunt Sarah.
MOM: They don’t need to know anything . . .
AMY:	Mom, just sign the paper and keep it simple,
please.
MOM: It’s Not That Simple!
Following performance of this 15-minute vignette at the
ELSI Congress and elsewhere, we encouraged discussion
among actors and the audience. We found that our dramatic
vignette helped to generate many questions about the implications of genome research on familial and professional relationships. For example, one bioethicist queried, “How would the
relationship between the Friedman family and Dr Hardy be
different if he or she were their regular physician as well as the
PI, and would that create a therapeutic misconception?”, while
another asked, “How does the amount of trust in Dr Hardy
impact on the informed consent process?” Several physician–
scientists concurred when their colleague commented that the
play’s dialogue contributed to their “better understanding” of
how professionals “feel about the [informed consent] process
when talking with families.”
Many found their role challenging, exacting an emotional
toll in weighing the varying interests and concerns of the family
unit engaged in genomic research, including the younger child
who appears not to be affected by the disorder. They remarked
that the play “heightened awareness” of their responsibility to
address the complexity of unique ethical and psychological
developmental issues when research involves vulnerable populations such as children, either as direct participants or indirectly due to family relations. Near-verbatim session notes from
the ELSI Congress reporter highlighted that the play brought to
life “the responsibility of parents to try to figure these issues out
for your family [when] they have ideas of their own.” There was
recognition of “the perspective of the ‘healthy kid’ who is going
to be victimized one way or another. But he’s not an adult, so he
can’t control his own destiny.”
The dramatic vignette also stimulated reactions of frustration:
“I thought the best part of the play was when they were reading
the informed consent form because it helped me to understand
how absurd they are . . . if you could do a dramatic reading of
an informed consent form for people who actually make and do
informed consent, it could be very effective.”
Our experiences using dialogue from existing theatre and our
dramatic vignette suggest that this creative approach has value
as a resource for fostering new perspectives with interdisciplinary groups.32 One of the ethicists participating at the Congress
expressed that “plays are very powerful and can be very effective
Volume 14 | Number 2 | February 2012 | Genetics in medicine
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at educating and getting professionals to think as well. It can
imprint on people the emotional content of the things we do.”
As a geneticist who “acted” the part of Bobby at our ELSI session reflected, “Playing a role forces you to think about things
from a different perspective. Playing a surly 19 year old makes
you think about the context of someone who’s really facing those
issues and how it is different from our academic perspective.”
We welcome our colleagues to collaborate with us in the
use of dramatic vignettes and evaluate their impact. Our goal
is to facilitate greater insight and discourse surrounding the
implications of genomic research on personal and professional
relationships. The complexity of contemporary ELSI issues are
brought to life through dramatic vignettes—“just because it is
not our life, places us in a moral position that is favorable for
perception and it shows us what it would be like to take up that
position in life.”33 Our experiences suggest that when the drama
of human relationships surrounding genetics are enacted by
the scientific, bioethical, and policy-making communities, the
dialogues create the potential to stimulate self-reflection and
new perceptions about their own roles as well—sparking “the
moral imagination”34 through the lens of others.
SUPPLEMENTARY MATERIAL
Supplementary material is linked to the online version of the paper
at http://www.nature.com/gim
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